Roche's Bispecific Antibody Passes Late-Stage Test, Paving Way for Broader Blood Cancer Approval

Roche's T cell engager Lunsumio succeeded in a Phase 3 trial for a slow-growing blood cancer, supporting a shift from accelerated to full approval and a wider indication. The bispecific antibody targets a specific protein on malignant B cells, engaging T cells to attack tumors. The positive confirmatory data could expand treatment options for patients with this lymphoma subtype.

Lunsumio, a bispecific antibody developed by Roche, has met its primary goal in a confirmatory Phase 3 study targeting a form of indolent (slow-growing) non-Hodgkin lymphoma. The therapy works by linking a protein found on malignant B cells to T cells, redirecting the immune system to destroy the cancer. This positive result follows earlier accelerated approval, which was conditional on such confirmatory evidence. The new data may support a transition to full regulatory approval and an expanded label, potentially broadening the patient population eligible for this treatment. The mechanism represents a growing class of cancer immunotherapies that harness T cells without requiring complex cell engineering.